| Literature DB >> 28468286 |
Kosuke Inoue1, Masao Omura2, Chiho Sugisawa3, Yuya Tsurutani4, Jun Saito5, Tetsuo Nishikawa6.
Abstract
The adrenocorticotropin (ACTH) stimulation test (AST) has been reported to be useful for diagnosing primary aldosteronism (PA), particularly for differentiating PA subtypes under 1-mg dexamethasone suppression (DS). The aim of our study was to clarify the effect of 1-mg DS on AST results. A retrospective cohort study was conducted using data for 48 patients (PA: 30/48). We estimated the difference in plasma aldosterone concentration (PAC) responsiveness to ACTH stimulation with single (AST alone) and combined (AST under 1-mg DS) tests within the same patient. We compared the diagnostic accuracy of these two tests for PA and the laterality of hyperaldosteronism. We found no differences in PAC responsiveness to ACTH stimulation between single and combined tests, and observed a significant positive linear relationship (30 min, R² = 0.75, p-value < 0.01). Both tests showed the highest diagnostic accuracy for PA following 30 min of ACTH stimulation. The ability to detect the laterality of hyperaldosteronism was inconsistent and differed according to the two definitions: lateralization ratio and the absolute aldosterone levels in adrenal venous sampling. PAC responsiveness to ACTH stimulation was similar for AST with and without 1-mg DS. AST can be performed under both conditions with similar accuracy to detect PA.Entities:
Keywords: adrenocorticotropin (ACTH) stimulation test; dexamethasone suppression test; primary aldosteronism
Mesh:
Substances:
Year: 2017 PMID: 28468286 PMCID: PMC5454861 DOI: 10.3390/ijms18050948
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Clinical characteristics a.
| Entry | PA ( | Non-PA ( | |
|---|---|---|---|
| U-PA ( | B-PA ( | ||
| Sex (Male), | 4 (30.8) | 5 (29.4) | 5 (27.8) |
| 0.62 | 0.58 | ||
| Age (years old) | 52.0 (39.3–60.4) | 48.9 (46.6–54.4) | 48.4 (41.9–53.9) |
| 0.87 | 0.52 | ||
| Body mass index (kg/m2) | 22.3 (20.9–25.3) | 25.5 (20.6–28.3) | 24.2 (21.3–28.8) |
| 0.25 | 0.32 | ||
| Systolic blood pressure (mmHg) | 168.0 (150.0–200.0) | 180.0 (167.0–196.0) | 141.0 (130.0–190.0) |
| 0.38 | 0.05 | ||
| Diastolic blood pressure (mmHg) | 100.0 (90.0–115.0) | 110.0 (95.0–120.0) | 88.0 (82.0–100.0) |
| 0.60 | 0.01 | ||
| Serum potassium (mmol/L) | 3.3 (3.1–3.9) | 4.0 (3.7–4.1) | 4.0 (3.9–4.2) |
| <0.01 | <0.01 | ||
| Serum sodium (mEq/L) | 142.0 (141.0–144.0) | 141.0 (140.0–142.0) | 140.0 (139.0–141.0) |
| 0.02 | <0.01 | ||
| eGFR (mL/min/1.73/m2) | 107.8 (97.0–114.0) | 107.1 (101.1–111.6) | 105.4 (98.1–113.2) |
| 0.85 | 0.97 | ||
| FEk (%) | 8.6 (6.2–10.8) | 5.0 (3.7–6.2) | 4.3 (3.8–5.3) |
| 0.04 | 0.01 | ||
| FEna (%) | 0.3 (0.2–0.5) | 0.4 (0.3–0.6) | 0.4 (0.3–0.6) |
| 0.48 | 0.50 | ||
Abbreviation: PA, primary aldosteronism; U-PA, unilateral PA; B-PA, bilateral PA; eGFR, estimated glomerular filtration rate; FEk, fractional excretion of potassium, FEna, fractional excretion of sodium. a Data are presented as median (interquartile range) unless otherwise indicated; b p-Value was calculated for each characteristic in the B-PA and Non-PA group compared to the U-PA group.
Comparison of PAC and F responsiveness to ACTH stimulation between combined and single tests a,b.
| Entry | PA ( | Non-PA ( | ||||
|---|---|---|---|---|---|---|
| U-PA ( | B-PA ( | |||||
| Combined | Single | Combined | Single | Combined | Single | |
| PAC (ng/dL), 0 min | 19.5 | 27.9 | 11.8 | 12.3 | 8.3 | 10.5 |
| (13.0–24.9) | (15.3–55.9) | (9.8–15.8) | (9.4–16.9) | (7.8–10.1) | (6.9–12.5) | |
| 0.05 | 0.62 | 0.40 | ||||
| PAC (ng/dL), 30 min | 69.1 | 79.5 | 29.2 | 33.2 | 23.2 | 26.2 |
| (29.5–122.0) | (38.5–103.0) | (22.4–35.1) | (26.6–39.8) | (20.2–29.1) | (19.1–30.3) | |
| 0.86 | 0.13 | 0.62 | ||||
| PAC (ng/dL), 60 min | 86.9 | 77.5 | 30.7 | 35.7 | 27.9 | 26.6 |
| (29.7–146.0) | (41.2–121.0) | (22.1–33.9) | (25.3–39.7) | (21.1–31.4) | (20.4–34.9) | |
| 0.55 | 0.12 | 0.51 | ||||
| F (µg/dL), 0 min d | 1.0 | 10.4 | 1.3 | 6.0 | 1.0 | 8.2 |
| (0.8–1.6) | (8.4–13.0) | (0.8–1.6) | (4.1–7.2) | (0.8–1.8) | (5.7–11) | |
| <0.01 | <0.01 | <0.01 | ||||
| F (µg/dL), 30 min | 15.2 | 19.5 | 17.4 | 19.4 | 18.1 | 20.9 |
| (13.4–16.9) | (18.3–21.4) | (16.2–21.1) | (17.6–21.5) | (15.2–20.6) | (17.7–24.8) | |
| <0.01 | <0.01 | <0.01 | ||||
| F (µg/dL), 60 min | 18.3 | 23.1 | 21.5 | 21.8 | 22.6 | 24.4 |
| (17.5–20.9) | (21.6–24.3) | (19.2–26.5) | (21.1–25.5) | (19.6–24.5) | (20.1–27.6) | |
| <0.01 | 0.44 | 0.01 | ||||
Abbreviations: PAC, plasma aldosterone concentration; F, serum cortisol; U-PA, unilateral PA; B-PA, bilateral PA. Conversion to SI units: PAC, ng/dL × 27.7 for pmol/L; F, µg/dL × 27.6 for nmol/L. a Data are presented as median (interquartile range) unless otherwise indicated; b ACTH (25 IU) was iv injected at 8:00 a.m., and blood samples were drawn at 0, 30, 60 min after injection to measure serum aldosterone and cortisol levels. When we perform AST under 1-mg DS, dexamethasone (1-mg) was administered at 11:00 p.m. the day before AST (single test: AST alone, and combined test: AST under 1-mg DS); c p-value was calculated for each value between combined and single test in each group; d Four and nine patients had serum cortisol levels during the 1-mg DS ≥ 3.0 μg/dL and 1.8 μg/dL (<3.0 μg/dL), respectively.
Comparison of the increase ratio of PAC and the PAC/F ratio after ACTH stimulation between combined and single tests a,b.
| Entry | PA ( | Non-PA ( | ||||
|---|---|---|---|---|---|---|
| U-PA ( | B-PA ( | |||||
| Combined | Single | Combined | Single | Combined | Single | |
| PAC 30 min/PAC 0 min | 3.3 | 1.8 | 2.5 | 2.3 | 2.7 | 2.5 |
| (2.4–4.4) | (1.5–3.0) | (1.9–2.9) | (2.1–2.7) | (2.4–3.0) | (2.1–3.4) | |
| 0.05 | 0.49 | 0.78 | ||||
| PAC 60 min/PAC 0 min | 2.9 | 1.9 | 2.3 | 2.3 | 2.9 | 2.8 |
| (2.5–5.0) | (1.7–3.0) | (2.1–2.9) | (2.0–2.9) | (2.7–3.6) | (2.5–3.5) | |
| 0.09 | 0.52 | 0.71 | ||||
| PAC/F, 0 min | 14.8 | 3.5 | 11.8 | 2.2 | 7.7 | 1.3 |
| (11.5–26.0) | (1.3–5.7) | (6.1–15.7) | (1.5–2.9) | (4.2–11.9) | (1.0–1.5) | |
| <0.01 | <0.01 | <0.01 | ||||
| PAC/F, 30 min | 4.5 | 3.8 | 1.7 | 1.6 | 1.3 | 1.4 |
| (1.7–8.5) | (1.5–5.3) | (1.4–1.9) | (1.4–2.0) | (1.0–1.8) | (0.9–1.7) | |
| <0.01 | 0.94 | 0.68 | ||||
| PAC/F, 60 min | 4.1 | 3.3 | 1.4 | 1.5 | 1.3 | 1.1 |
| (1.5–6.8) | (1.6–4.9) | (1.0–1.6) | (1.1–1.9) | (0.9–1.5) | (0.7–1.6) | |
| 0.05 | 0.23 | 0.85 | ||||
Abbreviations: PAC, plasma aldosterone concentration; F, serum cortisol; U-PA, unilateral PA; B-PA, bilateral PA. Conversion to SI units: PAC, ng/dL × 27.7 for pmol/L; F, µg/dL × 27.6 for nmol/L. a Data are presented as median (interquartile range) unless otherwise indicated; b ACTH (25 IU) was iv injected at 8:00 a.m., and blood samples were drawn at 0, 30, 60 min after injection to measure serum aldosterone and cortisol levels. When we perform AST under 1-mg DS, dexamethasone (1-mg) was administered at 11:00 p.m. the day before AST (single test: AST alone, and combined test: AST under 1-mg DS); c p-Value was calculated for each value between combined and single test in each group.
Figure 1Linear regression analysis of PAC responsiveness to ACTH stimulation between single (AST alone) and combined (AST under 1-mg DS) tests. (A) All patients: 30 min, R2 = 0.75, p-value < 0.01; 60 min, R2 = 0.76, p-value < 0.01; (B) PA patients: 30 min, R2 = 0.85, p-value < 0.01; 60 min, R2 = 0.85, p-value < 0.01. Abbreviations: PAC, plasma aldosterone concentration; ACTH, adrenocorticotropin; AST, ACTH stimulation test; DS, dexamethasone suppression; PA, primary aldosteronism.
ROC analysis of combined and single tests for detecting PA and PA subtypes in patients with PRA < 1.2 ng/mL/h a.
| Combined | PAC, 30 min | 26.1 | 76.7% | 73.3% | 0.77 |
| Single | PAC, 30 min | 29.1 | 73.3% | 66.7% | 0.78 |
| Combined | PAC, 30 min | 41.4 | 69.2% | 82.4% | 0.79 |
| Single | PAC, 30 min | 38.5 | 76.9% | 70.6% | 0.81 |
| Combined | PAC, 30 min | 41.4 | 47.4% | 72.7% | 0.54 |
| Single | PAC, 30 min | 38.5 | 52.6% | 54.6% | 0.54 |
Abbreviation: AUC, area under the curve; U-PA, unilateral PA; B-PA, bilateral PA; LR, lateralization ratio; AV, absolute value. Conversion to SI units: PAC, ng/dL × 27.7 for pmol/L. a Diagnostic accuracy for (A) PA in patients with PRA < 1.2 ng/mL/h, (B) U-PA defined by LR (≥2.6) in patients with PA, and (C) U-PA defined by AV (≥1400 ng/mL) in patients with PA. (single test: AST alone, and combined test: AST under 1-mg DS).
Results of adrenal venous sampling of a 48-year-old male patient with APmicroA a.
| Entry | Right Adrenal Grand | Left Adrenal Grand | LR | Affected Side | |||||
|---|---|---|---|---|---|---|---|---|---|
| Central Vein | Superior Branch | Lateral Branch | Inferior Branch | Central Vein | Superior Branch | Lateral Branch | |||
| PAC (ng/dL) | 465 | 532 | 1580 | 2180 | 683 | 734 | NA | 1.2 | Right |
| Cortisol (μg/dL) | 383 | 449 | 488 | 379 | 457 | 486 | NA | ||
Abbreviations: PAC, plasma aldosterone concentration; LR, lateralization ratio; NA, not available. Conversion to SI units: PAC, ng/dL × 27.7 for pmol/L; F, µg/dL × 27.6 for nmol/L. a After ACTH stimulation, blood samples were collected from the superior, lateral, and inferior branches of the right central adrenal vein and the superior and lateral branches of the left central adrenal vein, in addition to the bilateral central adrenal veins. APmicroA was defined as aldosterone-producing adenoma which was too small to detect using computer tomography.